The present invention relates to a dialysis machine having an extracorporeal blood circuit; a dialyzer; and a dialysate circuit, wherein a blood pump is arranged in the extracorporeal blood circuit; wherein the dialyzer has a dialysate membrane which separates its blood side from its dialysate side; wherein the dialysis machine has a control unit which is configured to carry out a conditioning cycle which comprises a conditioning phase in which an ultrafiltration rate exceeds the blood flow through the dialyzer conveyed by the blood pump.

A method for producing a blood filter, the blood filter being a filter for filtering blood, the method comprising providing a first layer; providing a block copolymer layer above the first layer; converting the block copolymer layer to a mask by selectively removing domains of the block copolymer layer; etching pores through the first layer in regions exposed by the mask; wherein a pore size is below 20 nm, the pore size preferably being 6.6 nm or smaller.

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

The invention relates to a device for hemodiafiltration with an extracorporeal circulation (10) for receiving blood to be purified and having a hemodialyzer and/or hemofilter (20) which is connected to the blood circulation (10), such that the blood circulation (10) has at least one inlet line (12, 14) for the supply of a replacement fluid upstream and downstream from the hemodialyzer and/or hemofilter (20), characterized in that the apparatus also comprises measurement apparatuses for recording the transmembrane pressure and/or hematocrit (HKT) and/or blood density, such that the measurement apparatuses are connected to a control unit (100) for controlling one or more of the transmembrane pressure and/or the hematocrit (HKT) and/or the blood density, the control unit (100) being constructed so that the control is implemented with the help of at least one of the infusion rates (Q.sub.spre, Q.sub.spost) of the replacement fluid (13, 15), and the blood to be purified is exposed to a high-frequency electromagnetic field and/or an electric DC field (70) before and/or during contact with the hemodialyzer and/or hemofilter (20).

A detoxification method for treating sepsis, microbial infections, and other inflammatory conditions includes the steps of inducing flow of patient blood through a blood treatment device consisting of a bioreactor inlet and outlet in fluid connection to the circulatory system of a patient. Biological agents including lipopolysaccharide (LPS) and extracellular adenosine triphosphate (ATP) contained within patient blood can be irreversibly detoxified by passage of patient blood over a bioreactor surface having attached or immobilized alkaline phosphatase enzymes and acyloxyacyl hydrolase enzyme, with the bioreactor being contained within the blood treatment device. The method uses continuous treatment of a patient's blood to convert LPS and extracellular ATP in blood into inhibitors of inflammation in vivo without adding any chemicals to the bloodstream of the patient.

A blood treatment method includes the steps of inducing flow of a patient's blood through a blood treatment device inlet and outlet in fluid connection to the circulatory system of the patient. Metastatic deoxyribonucleic acid (DNA) contained within patient blood is destroyed by passing a patient's blood over a bioreactor surface having attached or immobilized deoxyribonuclease 1 (DNase 1) enzyme. The blood treatment device which consists of a bioreactor containing immobilized DNase 1, enables continuous treatment of a patient's blood and increases the effective concentration of DNase 1 in a patient's bloodstream to convert metastasizing cancer DNA in blood into non-oncogenic nucleotide fragments in vivo without adding any chemicals to the blood of the patient.

A method for electrochemically filtering a bodily fluid in the treatment of a disease includes a pump to circulate the fluid through a collection container and an electromagnetic charging system. One of the cathode and anode leads is connected to a collection plate while the other of the cathode and anode leads is connected a patient to be treated. Inlet and outlet catheters are connected to patient to be treated. A predetermined voltage is applied across the anode lead and the cathode lead from a DC power supply, wherein circulating fluid from the patient passes through the collection container for removal of charged biological materials onto the collection plate. The fluid is returned back to the patient by the pump system.

Disclosed is a method for treating of Cockayne Syndrome (CS). Specifically, the invention pertains to a method for the extracorporeal treatment of a body fluid by removing the body fluid from a living body diseased with CS, and applying a targeted antibody conjugated to a moiety to at least one Cockayne Syndrome antigen in the body fluid, creating an antibody-antigen moiety complex, removing antibody-antigen moiety complex from the body fluid, and returning the purified body fluid to the body.

A blood reinfusion system for processing autologous blood for reinfusion into a patient. The system includes a blood reinfusion system having a blood processing canister with an internal fluid passageway. The internal fluid passageway includes a venturi region having a gravity-driven filtering system that is adapted to extract impurities from autologous blood without damaging the erythrocytes in the blood and, hence, inducing hemolysis of the erythrocytes in the blood, and loss of seminal native blood components, including native erythrocytes, platelets, white blood cells, plasma proteins and antibodies.